ArticleDiscover oncology2025
Pan‑cancer analysis of the oncogenic role of telomeric repeat binding factor 2 (TERF2) in human tumors and in vitro validation in gastric cancer by TERF2 knockdown.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTelomeric repeat binding factor 2 (TERF2), a key component of the Shelterin complex, is crucial for maintaining telomere integrity and genome stability. While the involvement of TERF2 in tumorigenesis and progression has been documented, comprehensive pan-cancer analyses of TERF2 across different malignancies remain scarce.
methodsIn the present study, the expression, mutations, immune cell infiltration, and interacting genes of TERF2 were systematically evaluated through bioinformatics analysis, and in vitro experiments were performed to elucidate the functional roles of TERF2 in gastric cancer.
resultsThe findings revealed that TERF2 was predominantly upregulated in cholangiocarcinoma (CHOL), diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), and thymoma (THYM), correlating with tumor progression. Amplification and mutations were identified as the primary alterations of TERF2, particularly associated with liver hepatocellular carcinoma (LIHC). Furthermore, TERF2 expression was linked to the infiltration of cancer-associated fibroblasts and immune cells in certain cancer types. Protein-protein interaction (PPI) analysis highlighted several genes associated with TERF2, including CTCF, DDX19A, MATR3, ZFP1, and ZFP90. Additionally, in vitro experiments demonstrated that TERF2 knockdown significantly suppressed the proliferation and migration of gastric cancer cells.
conclusionsThese results suggest that dysregulation and mutations of TERF2 are prevalent across various cancers, contributing to tumor immunity and acting as an oncogenic factor, thus positioning TERF2 as a potential therapeutic target in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.